Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Cirugía y cirujanos
versión On-line ISSN 2444-054Xversión impresa ISSN 0009-7411
Resumen
JIMENEZ-OROZCO, F. Alejandro et al. In vitro anti-proliferative effect and in vivo antitumor action of daphnetin in different tumor cells. Cir. cir. [online]. 2020, vol.88, n.6, pp.765-771. Epub 08-Nov-2021. ISSN 2444-054X. https://doi.org/10.24875/ciru.20000197.
Background:
The anti-inflammatory effects of daphnetin (7,8-dihidroxicoumarin) have been well-documented, but the potential of daphnetin as an anticancer agent is controversial and remains insufficiently explored.
Material and methods:
In this work, we evaluated the in vitro anti-proliferative effect of daphnetin in three cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, as well as its in vivo antitumor effect in four different types of mouse tumor.
Results:
With a correlation between in vitro and in vivo results, the tested cell types have different sensitivity to the compound. The following cell lines are arranged according to the in vitro anti-proliferative potency of daphnetin: B16 melanoma cells (inhibitory concentrations 50 [IC50] = 54 ± 2.8 µM) > mitoxantrone (MXT) breast adenocarcinoma cells (IC50 = 74 ± 6.4 µM) > C26 colon carcinoma cells (IC50 = 108 ± 7.3 µM). In vivo, the optimal antitumor dose of daphnetin was 40 mg/kg and the magnitudes of inhibition were the following: B16 tumor (48%) > MXT tumor (40%) > S180 fibrosarcoma tumor (30%) > C26 tumor (20%).
Conclusion:
Our results indicate that daphnetin might have an impact as adjuvant to improve the effectiveness of conventional chemotherapy.
Palabras llave : Daphnetin; Coumarins; Antiproliferation; Antitumor activity; Tumor chemotherapy.